Verapamil

Overview

Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like diltiazem and flunarizine, but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.

Indication

Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter. Given intravenously, it is indicated for the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutter. Verapamil is commonly used off-label for prophylaxis of cluster headaches.

Associated Conditions

Chronic Stable Angina Pectoris
Cluster Headache
Heart Rate
Hypertension
Paroxysmal Supraventricular Tachycardia (PSVT)
Supra-ventricular Tachyarrhythmias
Unstable Angina Pectoris
Vasospastic Angina

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers	2025/04/08	NCT06916897	Phase 1	Completed	Edgewise Therapeutics, Inc.
Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment	2025/03/27	NCT06897969	Phase 4	Not yet recruiting	Nishtar Medical University
Management of Acute Tinnitus With Migraine Medications	2025/01/29	NCT06799169	Phase 4	Recruiting	University of California, Irvine
Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients	2024/12/05	NCT06717685	Phase 3	Recruiting	Rashid Latif Medical College
Efficacy and Safety of HB-1 for Panic Disorder	2024/07/03	NCT06483789	Phase 2	Recruiting	Honeybrains Biotech LLC
Precision Administration of Anti-thymocyte Globulin With or Without Verapamil	2024/06/12	NCT06455319	Phase 2	Not yet recruiting	University of Florida
The Role of Verapamil in Radial Artery Spasm	2024/06/07	NCT06447688	Phase 4	Completed	Mersin Medicalpark Hastanesi
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects	2024/04/09	NCT06354556	Phase 1	Completed	Shandong Suncadia Medicine Co., Ltd.
Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin	2023/11/07	NCT06118684	Phase 1	Completed	EpiEndo Pharmaceuticals
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin	2023/09/11	NCT06031454	Phase 1	Completed	Guangdong Raynovent Biotech Co., Ltd

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
VERAPAMIL HYDROCHLORIDE	Bryant Ranch Prepack	63629-7894	ORAL	40 mg in 1 1	3/12/2022
VERAPAMIL HYDROCHLORIDE	A-S Medication Solutions	50090-5253	ORAL	180 mg in 1 1	12/6/2022
Verapamil Hydrochloride	American Health Packaging	60687-515	ORAL	240 mg in 1 1	8/21/2023
VERAPAMIL HYDROCHLORIDE	Denton Pharma, Inc. dba Northwind Pharmaceuticals	70934-739	ORAL	120 mg in 1 1	7/6/2020
VERAPAMIL HYDROCHLORIDE	Preferred Pharmaceuticals Inc.	68788-8338	ORAL	120 mg in 1 1	2/2/2023
Verapamil Hydrochloride	Amneal Pharmaceuticals LLC	70121-1585	INTRAVENOUS	2.5 mg in 1 mL	12/22/2022
VERAPAMIL HYDROCHLORIDE	Cadila Pharmaceuticals Limited	71209-047	ORAL	180 mg in 1 1	11/30/2022
Verapamil Hydrochloride	Proficient Rx LP	71205-129	ORAL	120 mg in 1 1	12/1/2018
Verapamil Hydrochloride	Physicians Total Care, Inc.	54868-5841	ORAL	300 mg in 1 1	6/27/2012
verapamil hydrochloride	Northwind Pharmaceuticals, LLC	51655-959	ORAL	180 mg in 1 1	3/22/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
ISOPTIN SR TABLET 240 mg	AbbVie Deutschland GmbH & Co. Kg, Famar A.V.E. Anthoussa Plant	SIN00344P	TABLET, FILM COATED	240.0 mg	4/22/1988

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
CORDILOX 180 SR verapamil hydrochloride 180mg tablet blister pack	54033	Viatris Pty Ltd	Medicine	A	12/4/1995
ISOPTIN SR verapamil hydrochloride 240mg tablet blister pack	12801	Viatris Pty Ltd	Medicine	A	10/8/1991
CORDILOX SR 240 mg Tablets	10681	Viatris Pty Ltd	Medicine	A	8/19/1991
TARKA 2/180 trandolapril 2mg & verapamil hydrochloride 180mg tablet	104663	Viatris Pty Ltd	Medicine	A	10/24/2005
ISOPTIN 180SR verapamil hydrochloride 180mg tablet blister pack	54032	Viatris Pty Ltd	Medicine	A	12/4/1995
ANPEC verapamil hydrochloride 80 mg tablet blister pack	316009	Viatris Pty Ltd	Medicine	A	11/7/2019
ISOPTIN verapamil hydrochloride 40mg tablet blister pack	65502	Viatris Pty Ltd	Medicine	A	3/25/1999
VERAPAMIL LRX verapamil hydrochloride 5 mg/2 mL solution for injection vial	404947	Luminarie Pty Ltd	Medicine	A	4/3/2024
TARKA 4/240 trandolapril 4mg & verapamil hydrochloride 240mg tablet	104664	Viatris Pty Ltd	Medicine	A	10/24/2005
ANPEC verapamil hydrochloride 40 mg tablet blister pack	316008	Viatris Pty Ltd	Medicine	A	11/7/2019

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
VERELAN	recro gainesville llc	02100487	Capsule (Sustained-Release) - Oral	180 MG	12/31/1994
VERAPAMIL HYDROCHLORIDE INJECTION USP	Sandoz Canada, Inc.	02166739	Liquid - Intravenous	2.5 MG / ML	12/31/1995
PENTA-VERAPAMIL - 120MG	pentapharm ltd.	02229598	Tablet - Oral	120 MG	6/6/1997
DOM-VERAPAMIL SR 240MG TABLETS	dominion pharmacal	02240321	Tablet (Extended-Release) - Oral	240 MG	12/16/1999
PMS-VERAPAMIL SR	Pharmascience Inc	02237791	Tablet (Extended-Release) - Oral	240 MG	9/1/1999
NU-VERAP SR	nu-pharm inc	02249812	Tablet (Extended-Release) - Oral	240 MG	7/19/2004
MYLAN-VERAPAMIL SR	Mylan Pharmaceuticals ULC	02210363	Tablet (Extended-Release) - Oral	240 MG	12/31/1996
MYLAN-VERAPAMIL SR	Mylan Pharmaceuticals ULC	02210355	Tablet (Extended-Release) - Oral	180 MG	12/31/1996
MYLAN-VERAPAMIL SR	Mylan Pharmaceuticals ULC	02450488	Tablet (Extended-Release) - Oral	180 MG	6/29/2016
MYLAN-VERAPAMIL	Mylan Pharmaceuticals ULC	02237922	Tablet - Oral	120 MG	5/11/1998

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access